DPP4 and hepatocellular carcinoma: Recent studies demonstrated that different hypoglycemic agents, including sodium glucose transporter inhibitor 2 inhibitors and dipeptidyl peptidase 4 inhibitors, suppressed the development of HCC following the improvement of glycemic control in a similar mouse model as that used in the present study [23,24].